source
- Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fatWave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…
- Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firmsSofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…BioPharma Dive · 3d agoDealPositive